This is “MARVEL” (not a comic): Molecule May Treat Muckle-Wells Disease

When I see “Marvel” and a picture like the one below…

…I see the makings of a superhero!

“A team of researchers at Trinity College Dublin has unearthed what they are calling a “marvel molecule.” Said to be capable of suppressing a key activator of various inflammatory diseases, it is hoped the molecule will lead to more effective treatments for conditions ranging from Alzheimer’s disease, to rheumatoid arthritis and motor neuron disease.”

This “Marvel” superhero, however to my surprise, is a molecule discovered to block an activator of inflammation as illustrated in that picture:

“The massive potential of the molecule lies in its ability to block a key activator of inflammatory diseases known as the NLRP3 inflammasome. Inflammasomes, protein clusters responsible for triggering a range of inflammatory processes, have long been considered potential therapeutic targets for treating a range of conditions.”

This “Marvel” superhero has a name:

“Through the study, the researchers found the molecule, dubbed MCC950, to be very promising in warding off multiple sclerosis. But what really pleased the researchers was the fact that the target, the NLRP3 inflammasome, also plays a strong role in the onset of other inflammatory diseases including Alzheimer’s, atherosclerosis, gout and Parkinson’s disease.”

And this “Marvel” superhero may reduce inflammation in patients with Muckle-Wells Disease, a part of the family of Cryopyrin-Associated Periodic Syndromes (CAPS):

“The researchers say that the molecule may also benefit sufferers of Muckle-Wells disease, a rare genetic disorder that can cause rashes, joint pain and other inflammations. Treating blood samples of patients with Muckle-Wells disease, the molecule was shown to block the rogue gene that triggers these recurring inflammatory processes.”

Ready to follow the adventures of our hero molecule, MCC950?

“This is an exciting development but it will take years and millions to get it to market. In the meantime, I am genetically disposed to alzheimers! We have to find a way to get these breakthroughs to the market faster!”

Read more…


James Stone

James Stone

James grew up in Switzerland, in a little town on a little lake among the foothills of the Alps. His very English first name is owed to his Australian mother. During university, James worked as a freelance journalist covering local news in the little country's capital. Once he completed his studies in political science and media, James moved to Sydney where he joined a media monitoring company. He remained in the media monitoring industry even after his return to Switzerland. Eventually, love brought James to America, where he joined the Patient Worthy editorial team.

Share this post

Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on print
Share on email